0001562180-23-008172.txt : 20231206
0001562180-23-008172.hdr.sgml : 20231206
20231206172023
ACCESSION NUMBER: 0001562180-23-008172
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231204
FILED AS OF DATE: 20231206
DATE AS OF CHANGE: 20231206
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pine Michael Craig
CENTRAL INDEX KEY: 0001904458
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-51122
FILM NUMBER: 231470526
MAIL ADDRESS:
STREET 1: C/O EYEPOINT PHARMACEUTICALS, INC.
STREET 2: 480 PLEASANT STREET, SUITE A-210
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001314102
STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826]
IRS NUMBER: 262774444
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: 617-926-5000
MAIL ADDRESS:
STREET 1: 480 PLEASANT STREET
STREET 2: SUITE B300
CITY: WATERTOWN
STATE: MA
ZIP: 02472
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida Corp.
DATE OF NAME CHANGE: 20080619
FORMER COMPANY:
FORMER CONFORMED NAME: pSivida LTD
DATE OF NAME CHANGE: 20050111
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0508
4
2023-12-04
false
0001314102
EyePoint Pharmaceuticals, Inc.
EYPT
0001904458
Pine Michael Craig
480 PLEASANT ST, STE A210
WATERTOWN
MA
02472
false
true
false
false
Chief Corp Dev.&Strat. Officer
true
Common Stock
2023-12-04
4
M
false
45000.00
12.62
A
50343.00
D
Common Stock
2023-12-04
4
S
false
45000.00
22.00
D
5343.00
D
Stock Option (Right to Buy)
12.62
2023-12-04
4
M
false
45000.00
0.00
D
2032-01-10
Common Stock
45000.00
55000.00
D
Includes 2,159 shares acquired on January 31, 2023 and 2,184 shares acquired on July 31,2023 pursuant to EyePoint's 2019 Employee Stock Purchase Plan.
The option to purchase will vest and become exercisable as follows: 25% at January 10th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.
/s/ Ron Honig, Attorney-in-Fact
2023-12-06